Edition:
United Kingdom

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

7.82HKD
25 Jun 2019
Change (% chg)

HK$-0.03 (-0.38%)
Prev Close
HK$7.85
Open
HK$7.82
Day's High
HK$7.95
Day's Low
HK$7.68
Volume
33,766,707
Avg. Vol
56,759,551
52-wk High
HK$12.46
52-wk Low
HK$4.53

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Says Unit Entered Into Joint Venture Contract With Akeso Biopharma
Monday, 17 Jun 2019 

June 17 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::CHIA-TAI TIANQING PHARMACEUTICAL ENTERED INTO JOINT VENTURE CONTRACT WITH AKESO BIOPHARMA, INC. TO ESTABLISH JV CO.REGISTERED CAPITAL OF JV SHALL BE IN RMB689.45 MILLION, OF WHICH RMB344.725 MILLION WILL BE CONTRIBUTED BY CHIA-TAI TIANQING IN CASH.JV FOR PURPOSE TO JOINTLY DEVELOP PROJECT OF RECOMBINANT HUMANIZED ANTI PD-1 MONOCLONAL ANTIBODY AK105 DRUG.  Full Article

Sino Biopharmaceutical Says Antifungal Drug Approved For Drug Registration
Monday, 17 Jun 2019 

June 17 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANTIFUNGAL DRUG "CASPOFUNGIN ACETATE FOR INJECTION" APPROVED FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION.  Full Article

Sino Biopharmaceutical Says "Gadoxetate Disodium Injection" Obtains Approval For Drug Registration
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"GADOXETATE DISODIUM INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Karolinska Development Proposes Measures To Resolve Convertible Loan
Wednesday, 29 May 2019 

May 29 (Reuters) - Karolinska Development AB ::REG-KAROLINSKA DEVELOPMENT'S BOARD OF DIRECTORS PROPOSES MEASURES TO RESOLVE THE COMPANY'S CONVERTIBLE LOAN.DIRECTED ISSUE OF SERIES B SHARES TO HOLDERS OF CONVERTIBLE LOAN ISSUED IN 2015.INITIATES A NEW COLLABORATION WITH SINO BIOPHARMA TO OPEN ASIAN MARKET FOR NORDIC INNOVATIONS..TO FACILITATE CONVERSION OF OUTSTANDING SEK 329 MILLION NOMINAL AMOUNT TOGETHER WITH ACCRUED INTEREST.COMPLETE TERMS OF DIRECTED ISSUE, INCLUDING SUBSCRIPTION PRICE, ARE EXPECTED TO BE ANNOUNCED AT LATEST ON JUNE 26, 2019.SINO BIOPHARMA AND CERTAIN OTHER OWNERS TO SUBMIT SUBSCRIPTION COMMITMENTS CORRESPONDING TO THEIR CONVERTIBLE LOAN.SUBSCRIPTION PRICE PROPOSED TO BE CALCULATED AS VOLUME-WEIGHTED AVERAGE SHARE PRICE (VWAP) 15 TRADING DAYS ENDING TWO DAYS PRIOR TO AGM, WITH DISCOUNT OF 3% APPLIED TO VWAP.PLANS TO SET UP BRANCH OFFICE IN CHINA WITH TASK TO BRIDGE THIS GAP BY OPENING ASIAN MARKET FOR NORDIC INNOVATIONS.  Full Article

Sino Biopharmaceutical Says Unit's Drug Got Approvals Of Drug Supplementary Application
Tuesday, 28 May 2019 

May 28 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::PALONOSETRON HYDROCHLORIDE INJECTION MADE BY UNIT GOT 2 APPROVALS OF DRUG SUPPLEMENTARY APPLICATION.APPROVALS BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article

Sino Biopharmaceutical Says Unit's "Apixaban Tablet" Got Drug Registration Approval In PRC
Wednesday, 22 May 2019 

May 22 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::UNIT'S APIXABAN TABLET GETS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says "Gefitinib Tablet" Obtained Approval For Drug Registration
Monday, 20 May 2019 

May 20 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"GEFITINIB TABLET" OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA.  Full Article

Sino Biopharmaceutical Says Unit Gets Approval For Generic Drugs
Wednesday, 24 Apr 2019 

April 24 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC APPROVED CONSISTENCY OF QUALITY & EFFICACY EVALUATION FOR GENERIC DRUGS OF UNIT.  Full Article

Sino Biopharmaceutical, As Borrower, Enters Facility Agreement
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::CO AS BORROWER ENTERED A FACILITY AGREEMENT FOR A TERM LOAN FACILITY IN AGGREGATE PRINCIPAL AMOUNT US$1.0 BILLION.  Full Article

Sino Biopharmaceutical Says Profit Of Group For Year Is Expected To Increase Significantly
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::PROFIT OF GROUP FOR YEAR IS EXPECTED TO INCREASE SIGNIFICANTLY.PROFIT ATTRIBUTABLE FOR YEAR EXPECTED TO INCREASE TO A RANGE OF ABOUT RMB8,908.37 MILLION TO ABOUT RMB9,283.71 MILLION.EXPECTED RESULT DUE TO CERTAIN PROFIT OR LOSS ITEMS THAT ARE REQUIRED TO BE RECOGNIZED IN ACCOUNTS OF CO.  Full Article

Hong Kong stocks inch down on China growth worries

* Hang Seng falls 0.7%, H-shares 0.5% lower; slightly up for week